SANTA CLARA, Calif., March 14, 2017 /PRNewswire/ -- Cardiva Medical, an innovator in the field of vascular closure, today
The financing will be used to continue the rapid commercial expansion of the VASCADE Vascular Closure System – and to fund Cardiva's proprietary, next generation closure technologies that are in development.
"We are pleased to welcome the affiliates of Luther King Capital Management as a new investor, and grateful for the continued support of our existing investors," said John Russell, President and CEO of Cardiva Medical. "Our mission is focused on reducing access site complications for the millions of patients who undergo vascular procedures each year. VASCADE has made a difference for over 100,000 patients in the United States since commercial launch just three years ago and adoption continues to grow rapidly. This financing will enable us to fully execute our commercial growth and development programs."
"VASCADE has demonstrated an unprecedented safety profile for patients – which is fueling Cardiva's rapid growth rate" said Michael Bornitz of Luther King Capital Management. "We are excited to be part of that growth story and the expansion of Cardiva's technology into new areas."
About the VASCADE Vascular Closure System and RESPECT StudyThere are over 6 million interventional procedures a year in the United States alone, and bleeding at the access site remains the number one source of complications for these patients. The VASCADE Vascular Closure System is the only closure system to demonstrate a statistically significant reduction in access site complications in a prospective, randomized controlled clinical trial – called RESPECT. The RESPECT study included 420 patients at 20 U.S. centers, comparing VASCADE to manual compression for femoral arterial closure.
About Cardiva Medical, Inc.Cardiva Medical, Inc is a privately held medical device company with headquarters in Santa Clara, California. For further information, visit our website at www.cardivamedical.com.
Media Contact: Lisa Garrett Chief Financial Officer Cardiva Medical, Inc. Phone: 408-470-7170 Lisa_Garrett@cardivamedical.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cardiva-medical-raises-30-million-300422356.html
SOURCE Cardiva Medical
Subscribe to our Free Newsletters!
Cyanosis is the bluish or purplish discoloration of the skin and mucus membranes due to lack of ...
Find out about travel shots or vaccination before you travel to your destination country. Travel ...
Hay fever is caused by allergy to pollen and is characterized by runny or blocked nose, sneezing, ...View All